- Home
- SOTK vs OTLK Comparison
SOTK vs OTLK Comparison
Compare SOTK & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOTK
- OTLK
- Stock Information
- Founded
- SOTK 1975
- OTLK 2010
- Country
- SOTK United States
- OTLK United States
- Employees
- SOTK N/A
- OTLK N/A
- Industry
- SOTK Industrial Machinery/Components
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOTK Technology
- OTLK Health Care
- Exchange
- SOTK Nasdaq
- OTLK Nasdaq
- Market Cap
- SOTK 58.5M
- OTLK 48.3M
- IPO Year
- SOTK 1987
- OTLK 2016
- Fundamental
- Price
- SOTK $3.63
- OTLK $1.71
- Analyst Decision
- SOTK Hold
- OTLK Strong Buy
- Analyst Count
- SOTK 1
- OTLK 5
- Target Price
- SOTK N/A
- OTLK $9.60
- AVG Volume (30 Days)
- SOTK 5.6K
- OTLK 883.5K
- Earning Date
- SOTK 07-10-2025
- OTLK 08-13-2025
- Dividend Yield
- SOTK N/A
- OTLK N/A
- EPS Growth
- SOTK N/A
- OTLK N/A
- EPS
- SOTK 0.08
- OTLK 0.83
- Revenue
- SOTK $20,504,381.00
- OTLK N/A
- Revenue This Year
- SOTK N/A
- OTLK N/A
- Revenue Next Year
- SOTK $9.53
- OTLK $379.84
- P/E Ratio
- SOTK $47.25
- OTLK $2.03
- Revenue Growth
- SOTK 4.08
- OTLK N/A
- 52 Week Low
- SOTK $3.50
- OTLK $0.87
- 52 Week High
- SOTK $6.05
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- SOTK 41.21
- OTLK 48.05
- Support Level
- SOTK $3.68
- OTLK $1.65
- Resistance Level
- SOTK $3.88
- OTLK $2.04
- Average True Range (ATR)
- SOTK 0.12
- OTLK 0.12
- MACD
- SOTK -0.00
- OTLK -0.02
- Stochastic Oscillator
- SOTK 13.04
- OTLK 15.38
About SOTK Sono-Tek Corporation
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.